アロプリノールは,慢性心不全における内皮機能障害を改善します.
Colin A J Farquharson1, Robert Butler, Alexander Hill
1Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK.
Circulation
|July 10, 2002
まとめ
アロプリノールは,酸化的ストレスを軽減することによって,慢性心不全患者の内皮機能不全を大幅に改善しました. これは,心血管疾患および運動能力に対する潜在的な利点を示唆しています.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 酸化ストレス研究 酸化ストレス研究
背景:
- 酸化ストレスが慢性心不全における内皮機能不全に関与している.
- ザンチン酸化酵素は,酸化ストレスを引き起こす重要な酵素です.
研究 の 目的:
- 慢性心不全における内皮機能不全に対するアルロプリノールの効果を調査する.
- アロピュリノールがこれらの患者の酸化ストレスマーカーを減少させるかどうかを判断する.
主な方法:
- ランダム化,プラセボ対照,双盲のクロスオーバー研究で,慢性心不全の11人の患者 (ニューヨーク心臓協会II-IIIクラス) が参加した.
- 患者は1ヶ月間,毎日300mgのアロプリノールまたはプラセボを投与された.
- 内皮機能は,アセチルコリン,ニトロプルーシド,ベラパミルによる前腕静脈閉塞プレシスモグラフィーを用いて評価されました.
- プラズママロンディアルデヒド濃度は,酸化ストレスマーカーとして測定されました.
主要な成果:
- アロプリノールは,プラセボと比較してアセチルコリンに対する前腕の血流反応を著しく改善した (181+/-19% vs. 120+/-22%,P=0.003).
- ニトロプロシドまたはヴェラパミルに対する反応において,治療グループ間の有意な差異は観察されなかった.
- アロプリノール治療により,血マロンディアルデヒド濃度 (346+/-128 nmol/L vs. 461+/-101 nmol/L,P=0.03) が著しく低下し,酸化ストレスが軽減されたことを示した.
結論:
- アロプリノールは,慢性心不全の患者の内皮機能不全を効果的に改善します.
- これらの発見は,アルロピュリノールが,心血管疾患の減少と,この患者集団における運動能力の向上における治療的利点を提供することを示唆しています.
関連する概念動画
Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
